MedTrace Logo

Ticagrelor China Pharmacokinetic/Pharmacodynamic Study

NCT02064985 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 61

Last updated 2016-05-11

Study results available
· View outcomes & findings →

Summary

open label, single centre, randomised, Phase IV, pharmacokinetic, pharmacodynamic, and safety study to evaluate single and multiple doses of 45, 60, and 90 mg of ticagrelor in Chinese patients with stable coronary heart disease

Conditions

  • Stable Coronary Heart Disease (CHD)

Interventions

DRUG

Inhibition of Platelet Aggregation by "Brilinta"(Ticagrelor)

To determine the Inhibition of Platelet Aggregation (IPA) profiles of single and multiple doses of ticagrelor 45, 60, and 90 mg in Chinese patients with stable coronary heart disease (CHD) on chronic low dose ASA (75-100mg daily).

Sponsors & Collaborators

Principal Investigators

  • Haiyan Li, PhD · The 3rd Hospital of Peking University

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2014-02-28
Primary Completion
2014-11-30
Completion
2014-11-30

Countries

  • China

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02064985 on ClinicalTrials.gov